Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma: A phase II trial

Cancer

Volumn 82, Issue 7, 1998, Pages 1352-1358

  Rini, Brian I ^a   Stadler, Walter M ^a   Spielberger, Ricardo T ^b   Ratain, Mark J ^a   Vogelzang, Nicholas J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Granulocyte macrophage colony stimulating factor; Immunotherapy; Pentoxifylline; Renal cell carcinoma

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; IMMUNOSTIMULATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PENTOXIFYLLINE; SURVIVAL RATE; VASODILATOR AGENTS;

EID: 0032055155     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980401)82:7<1352::AID-CNCR19>3.0.CO;2-5     Document Type: Article

References (24)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. McDougal WS, Garnick MB. Clinical signs and symptoms of renal cell carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS. Comprehensive textbook of genitourinary oncology. Baltimore: Williams and Wilkens, 1996:154-9.
3. Hawkins MJ. Immunotherapy with high-dose interleukin 2, In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS. Comprehensive textbook of genitourinary oncology. Baltimore: Williams and Wilkens, 1996:242-7.
4. Stadler WM, Vogelzang NJ. Low dose interleukin-2 therapy in the treatment of metastatic renal cell carcinoma. Semin Oncol 1995;22:67-73.
5. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus of interleukin-2. JAMA 1994;271:907-13.
6. Sieff CA. Hematopoietic growth factors. J Clin Invest 1987;79: 1549-57.
7. Clark SC, Kamer R. The human hematopoetic colony-stimulating factors. Science 1987;236:1229-37.
8. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trochenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;190:83-93.
9. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176:1693-1702.
10. Szabolcs P, Moore MA, Young JW. Expansion of immuno-stimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 1995;154:5851-61.
11. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Lenitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43.
12. Sisson SD, Dinarello CA. Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood 1988;72: 1368-74.
13. Wos E, Olencki T, Tuason L, Budd GT, Peereboom D, Sandstrom K, et al. Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer 1996; 77:1149-53.
14. Horvath CJ, Ferro TJ, Jesmok G, Malik AB. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. Proc Natl Acad Sci U S A 1988;85:9219-23.
15. Noel P, Nelson S, Bokulic R, Bagby G, Lippton H, Lipscomb G, et al. Pentoxifylline inhibits lipopolysaccharide induced serum tumor necrosis factor and mortality. Life Sciences 1990;47:1023-9.
16. Han J, Thompson P, Beutler B. Dexamethasone and pentoxfylline inhibit endotoxin induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-4.
17. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Keltner P, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991;78:1205-11.
18. Sagaster P, Micksike M, Flamm J, Ludwig H. Randomized study using IFN-"versus IFN" plus Coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 1995;6:999-1003.
19. Schornagel JH, Verweij J, ten Bokkel Huninik WW, Klijn JG, de Mulder PH, Debruyne FM, et al. Phase II study of recombinant Interferon alpha 2a and vinblastine in advanced renal cell carcinoma. J Urol 1989;142:253-6.
20. Stadler WM, Rybak ME, Vogelzang NJ. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer 1995;76:1629-33.
21. Steger GG, Kaboo R, DeKernion JB, Figlin R, Bellegrun A. The effects of granulocyte-macrophage colony-stimulating factor on tumor-infiltrating lymphocytes from renal cell carcinoma. Br J Cancer 1995;72:101-7.
22. Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, et al. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. Clin Cancer Res 1996;2:319-30.
23. Pyrkonen S, Salminen E, Lehtomen T. Recombinant interferon alpha 2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma: a phase III study [abstract]. Proc Amer Soc Clin Oncol 1996;15:614.
24. Tolcher AW, Giusti RM, O'Shaughnessy JA, Cowan KH. Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases. Cancer Invest 1995;13:188-92.